

## References

1. DeFronzo RA. *International Textbook of Diabetes Mellitus*. 3rd ed. Chichester, West Sussex; Hoboken, NJ: John Wiley; 2004.
2. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. *Diabetes* 1979; **28**:1039–1057.
3. WHO Expert Committee on Diabetes Mellitus, World Health Organization. WHO Expert Committee on Diabetes Mellitus Second Report. Geneva: World Health Organization; 1980.
4. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report no. 99.2. Geneva: World Health Organisation; 1999.
5. WHO Study Group on Diabetes Mellitus, World Health Organization. Diabetes mellitus report of a WHO Study Group. Geneva: World Health Organization; 1985.
6. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; **20**:1183–1197.
7. Genuth S, Alberti KG, Bennett P, Buse J, DeFronzo R, Kahn R *et al*. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003; **26**:3160–3167.
8. Kuzuya T, Matsuda A. Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. *Diabetes Care* 1997; **20**:219–220.
9. Laakso M, Pyorala K. Age of onset and type of diabetes. *Diabetes Care* 1985; **8**:114–117.
10. Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. *Diabetes Care* 1993; **16**:902–910.
11. Tuomilehto J, Zimmet P, Mackay IR, Koskela P, Vidgren G, Toivanen L *et al*. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. *Lancet* 1994; **343**:1383–1385.
12. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. *Diabetes* 1988; **37**:736–744.
13. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes. *Diabetes Care* 2002; **25**:1862–1868.
14. The DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. *Diabetes Care* 2003; **26**:61–69.
15. The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and two-hour diagnostic criteria. *Arch Intern Med* 2001; **161**:397–405.
16. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D *et al*. Postprandial glucose regulation and diabetic complications. *Arch Intern Med* 2004; **164**:2090–2095.
17. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. *Diabetes Care*. 1984; **7**:491–502.
18. Pecoraro RE, Chen MS, Porte D Jr. Glycosylated hemoglobin and fasting plasma glucose in the assessment of outpatient glycaemic control in NIDDM. *Diabetes Care* 1982; **5**:592–599.
19. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. *Lancet* 1999; **354**:617–621.
20. The DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? *Diabetes Care* 2003; **26**:688–696.
21. The DECODE Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. *BMJ* 1998; **317**:371–375.
22. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR *et al*. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. *Diabetes Care* 1998; **21**:518–524.
23. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. *Diabetes Care* 1998; **21**:1414–1431.
24. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004; **27**:1047–1053.
25. Engelgau MM, Colagiuri S, Ramachandran A, Borch-Johnsen K, Narayan KM. Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions. *Diabetes Technol Ther* 2004; **6**:874–882.

26. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. *Diabetes Care* 2000;23:1563–1580.
27. Tuomilehto J, Lindstrom J. The major diabetes prevention trials. *Curr Diab Rep* 2003;3:115–122.
28. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. *Diabetes Care* 2003;26:2910–2914.
29. Qiao Q, Hu G, Tuomilehto J, Nakagami T, Balkau B, Borch-Johnsen K *et al*. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. *Diabetes Care* 2003;26: 1770–1780.
30. Bartnik M, Rydén L, Malmberg K, Öhrvik J, Pyörälä K, Standl E, Ferrari R, Simoons M, Soler-Soler J, on behalf of the Euro Heart Survey Investigators. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease. *Heart* 2007;93:72–77.
31. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. *Diabetes Care* 2003;26:725–731.
32. Saaristo T, Peltonen M, Lindstrom J, Saarikoski L, Sundvall J, Eriksson JG *et al*. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. *Diab Vasc Dis Res* 2005;2:67–72.
33. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S *et al*. Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. *Diabetes Care* 2005;28:2637–2643.
34. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening—The Kora survey 2000. *Diabetologia* 2003;46:182–189.
35. Orchard TJ. The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. *Ann Med* 1996;28:323–333.
36. King H, Rewers M and WHO Ad Hoc Diabetes Reporting Group. Global Estimates for Prevalence of Diabetes Mellitus and Impaired Glucose Tolerance in Adults. *Diabetes Care* 1993;16:157–177.
37. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. Indian Diabetes Prevention Programme (IDPP). *Diabetologia* 2006; 49:289–297.
38. Qiao Q *et al*. Epidemiology and Geography of Type 2 Diabetes Mellitus. In DeFronzo QA *et al.*, eds. *International Textbook of Diabetes Mellitus*. John Wiley & Sons; Milan: 2004. p33–56.
39. Laakso M., Hyperglycaemia and cardiovascular disease in type 2 diabetes. *Diabetes* 1999;48:937–942.
40. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. *Diabetes Care* 2000; 23:1516–1526.
41. Lee ET, Keen H, Bennett PH, Fuller JH, Lu M. Follow-up of the WHO Multinational Study of Vascular Disease in Diabetes: general description and morbidity. *Diabetologia* 2001;44(Suppl. 2):S3–S13.
42. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. *Diabetologia* 2001;44(Suppl. 2):S14–S21.
43. Koivisto VA, Stevens LK, Mattcock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. *Diabetes Care* 1996;19:689–697.
44. Tuomilehto J, Borch-Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C, Reunanen A. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. *Diabetologia* 1998;41:784–790.
45. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B *et al*. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005; 353:2643–2653.
46. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ. Insulin resistance-related factors, but not glycaemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetes Care* 2003;26:1374–1379.
47. Juutilainen A *et al*. Type 2 diabetes as a ‘coronary heart disease equivalent’: an 18-year prospective population-based study in Finnish subjects. *Diabetes Care* 2005;28:2901–2907.
48. Hu FB *et al*. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. *Arch Intern Med* 2001;161:1717–1723.
49. Hu G *et al*. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. *Diabetologia* 2005;48:856–861.
50. International Collaborative Group. Asymptomatic hyperglycaemia and coronary heart disease: a series of papers by the International Collaborative Group based on studies in fifteen populations. *J Chron Dis* 1979;32:683–837.
51. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycaemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. *Diabetes Care* 1998;21:1236–1239.
52. Barzilay JI *et al*. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. *Lancet* 1999;354:622–625.
53. Scherthner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. *J Clin Endocrinol Metab* 2004;89:6068–6076.
54. Charbonnel BH, Matthews DR, Scherthner G, Hanefeld M, Brunetti P; QUARTET Study Group. A long-term comparison of pioglitazone and glimepiride in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. *Diabet Med* 2005;22:399–405.
55. Borch-Johnsen K. The new classification of diabetes mellitus and IGT: a critical approach. *Exp Clin Endocrinol Diabetes* 2001;109(Suppl. 2):S86–S93.
56. Fontbonne A *et al*. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. *Diabetologia* 1989;32:300–304.
57. Fuller JH *et al*. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. *Lancet* 1980;1:1373–1376.
58. Lowe LP *et al*. Diabetes, asymptomatic hyperglycaemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. *Diabetes Care* 1997;20:163–169.
59. Rodriguez BL *et al*. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: The Honolulu Heart Programme. *Diabetes Care* 1999;22:1262–1265.
60. Saydah SH *et al*. Postchallenge hyperglycaemia and mortality in a national sample of U.S. adults. *Diabetes Care* 2001;24:1397–1402.
61. Scheidt-Nave C *et al*. Sex differences in fasting glycaemia as a risk factor for ischemic heart disease death. *Am J Epidemiol* 1991;133:565–576.
62. Shaw JE *et al*. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. *Diabetologia* 1999;42:1050–1054.
63. Tominaga M *et al*. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. *Diabetes Care* 1999;22:920–924.
64. Coutinho M *et al*. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. *Diabetes Care* 1999;22:233–240.
65. Pyörälä K *et al*. Glucose tolerance and coronary heart disease: Helsinki Policemen Study. *J Chronic Dis* 1979;32:729–745.
66. Cheung NW, Wong VW, McLean M. The Hyperglycaemia: Intensive Insulin Infusion in Infarction (HI-5) Study. A randomized controlled trial of insulin infusion therapy for myocardial infarction. *Diabetes Care* 2006;29:765–770.
67. Saydah SH *et al*. Subclinical states of glucose intolerance and risk of death in the U.S. *Diabetes Care* 2001;24:447–453.
68. The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. *Diabetologia* 2003;46:608–617.
69. The DECODE Study Group. Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). *Diabetes Care* 1999;22:1667–1671.
70. Chiasson JL *et al*. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA* 2003;290:486–494.
71. UKPDS, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:837–853.

72. Hanefeld M *et al.* Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. *Diabetologia* 1996;**39**:1577-1583.
73. Hanefeld M *et al.* Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. *Eur Heart J* 2004;**25**:10-16.
74. Tunstall-Pedoe H *et al.* Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. *Circulation* 1994;**90**:583-612.
75. Tuomilehto J, Kuulasmaa K. WHO MONICA Project: assessing CHD mortality and morbidity. *Int J Epidemiol* 1989;**18**(Suppl. 1):S38-S45.
76. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. *JAMA* 1979;**241**:2035-2038.
77. Barrett-Connor EL *et al.* Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. *JAMA* 1991;**265**:627-631.
78. Juutilainen A *et al.* Gender difference in the impact of Type 2 diabetes on coronary heart disease risk. *Diabetes Care* 2004;**27**:2898-2904.
79. Janghorbani M *et al.* A prospective population based study of gender differential in mortality from cardiovascular disease and 'all causes' in asymptomatic hyperglycaemics. *J Clin Epidemiol* 1994;**47**:397-405.
80. Kanaya AM *et al.* Glycaemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2003;**138**:1-9.
81. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. *BMJ* 2006;**332**:73-78.
82. Adams HP Jr *et al.* Prevalence of diabetes mellitus among patients with subarachnoid hemorrhage. *Arch Neurol* 1984;**41**:1033-1035.
83. Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke? *Am J Epidemiol* 1988;**128**:116-123.
84. Kittner SJ *et al.* Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. *JAMA* 1990;**264**:1267-1270.
85. Lehto S *et al.* Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. *Stroke* 1996;**27**:63-68.
86. Rodriguez BL *et al.* Risk of hospitalized stroke in men enrolled in the Honolulu Heart Programme and the Framingham Study: A comparison of incidence and risk factor effects. *Stroke* 2002;**33**:230-236.
87. Tuomilehto J *et al.* Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. *Stroke* 1996;**27**:210-215.
88. Wolf PA *et al.* Probability of stroke: a risk profile from the Framingham Study. *Stroke* 1991;**22**:312-318.
89. Yusuf HR *et al.* Impact of multiple risk factor profiles on determining cardiovascular disease risk. *Prev Med* 1998;**27**:1-9.
90. Ayala C *et al.* Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age, 1995-1998. *Stroke* 2002;**33**:1197-1201.
91. Mohr JP *et al.* The Harvard Cooperative Stroke Registry: a prospective registry. *Neurology* 1978;**28**:754-762.
92. Qureshi AI *et al.* Risk factors for multiple intracranial aneurysms. *Neurosurgery* 1998;**43**:22-26; discussion 26-27.
93. Thorvaldsen P *et al.* Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. *Stroke* 1995;**26**:361-367.
94. Longstreth WT Jr *et al.* Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. *Stroke* 2002;**33**:2376-2382.
95. Vermeer SE *et al.* Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. *Stroke* 2002;**33**:21-25.
96. Simpson RK Jr *et al.* The influence of diabetes mellitus on outcome from subarachnoid hemorrhage. *Diabetes Res* 1991;**16**:165-169.
97. Hu HH *et al.* Prevalence of stroke in Taiwan. *Stroke* 1989;**20**:858-863.
98. Oppenheimer SM *et al.* Diabetes mellitus and early mortality from stroke. *BMJ (Clin Res Ed)* 1985;**291**:1014-1015.
99. Kiers L *et al.* Stroke topography and outcome in relation to hyperglycaemia and diabetes. *J Neurol Neurosurg Psychiatry* 1992;**55**:263-270.
100. Kushner M *et al.* Relation of hyperglycaemia early in ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome. *Ann Neurol* 1990;**28**:129-135.
101. Toni D *et al.* Does hyperglycaemia play a role on the outcome of acute ischaemic stroke patients? *J Neurol* 1992;**239**:382-386.
102. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. *Diabetologia* 1978;**14**:363-370.
103. Fuller JH, Stevens LK, Wang SL. International variations in cardiovascular mortality associated with diabetes mellitus: the WHO Multinational Study of Vascular Disease in Diabetes. *Ann Med* 1996;**28**:319-322.
104. Matz K *et al.* Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. *Diabetes Care* 2006;**29**:792-797.
105. Vancheri F *et al.* Impaired glucose metabolism in patients with acute stroke and no previous diagnosis of diabetes mellitus. *QJM* 2005;**98**:871-878.
106. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. *JAMA* 1999;**281**:1291-1297.
107. American Diabetes Association. Clinical practice recommendations 1999. *Diabetes Care* 1999;**22**(Suppl. 1):S1-S114.
108. Tuomilehto J, Lindstrom J, Eriksson JG *et al.* Prevention of type 2 diabetes mellitus by changes in life style among subjects with impaired glucose tolerance. *N Engl J Med* 2001;**344**:1343-1350.
109. Knowler WC, Barrett-Connor E, Fowler SE *et al.* Reduction in the incidence of type 2 diabetes with life style intervention or metformin. *N Engl J Med* 2002;**346**:393-403.
110. American College of Endocrinology. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. *Endocr Pract* 2002;**8**(Suppl. 1):1-82.
111. Franciosi M, De Berardis G, Rossi MC *et al.* Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. *Diabetes Care*, 2005;**28**:1187-1194.
112. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG *et al.* The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 1996;**335**:1001-1009.
113. Kylin E. Studies of the hypertension-hyperglycaemia hyperuricemia syndrome. (Studien ueber das hypertonie-hyperglykämie-hyperurikämiesyndrom.) *Zentralblatt fuer Innere Medizin* 1923;**44**:105-127.
114. Vague J. La différenciation sexuelle. Facteur determinant des formes de l'obésité. *Press Med* 1947;**30**:339-340.
115. Hanefeld M, Leonhardt W. Das metabolische syndrom. *Dtsch Ges Wesen* 1981;**36**:545-551.
116. Kissebah AH, Vydelingum N, Murray R *et al.* Relation of body fat distribution to metabolic complications of obesity. *J Clin Endocrinol Metab* 1982;**54**:254-260.
117. Krotkiewski M *et al.* Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. *J Clin Invest* 1983;**72**:1150-1162.
118. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988;**37**:1595-1607.
119. Haffner SM, Valdez RA, Hazuda HP *et al.* Prospective analysis of the insulin-resistance syndrome (syndrome X). *Diabetes* 1992;**41**:715-722.
120. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. *Am J Cardiol* 1999;**83**:25F-29F.
121. Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. *Am J Epidemiol* 2000;**152**:908-911; discussion 912.
122. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;**15**:539-553.
123. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998;**339**:1349-1357.
124. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K *et al.* Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. *Diabetes Metab* 2002;**28**:364-376.
125. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). *Diabet Med* 1999;**16**:442-443.
126. Adult Treatment Panel III. Third Report of the National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;**106**:3143-3421.

127. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA* 2001;**285**:2486–2497.
128. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome, 25–26 August 2002, Washington, DC. *Diabetes Care* 2003;**26**:933–939.
129. American College of Endocrinology Task Force on the Insulin Resistance Syndrome, American College of Endocrinology Position Statement on the Insulin Resistance Syndrome. *Endocr Pract* 2003;**9**:237–252.
130. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. *Lancet* 2005;**366**:1059–1062.
131. Isomaa B *et al.* Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001;**24**:683–689.
132. Lakka HM *et al.* The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;**288**:2709–2716.
133. The DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. *Arch Intern Med* 2004;**164**:1066–1076.
134. Juutilainen A *et al.* Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women. *Diabetologia* 2006;**49**:56–65.
135. Resnick HE *et al.* Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: The Strong Heart Study. *Diabetes Care* 2003;**26**:861–867.
136. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. *Atherosclerosis* 2004;**173**:309–314.
137. Hunt KJ *et al.* National Cholesterol Education Programme versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. *Circulation* 2004;**110**:1251–1257.
138. Stern MP *et al.* Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? *Diabetes Care* 2004;**27**:2676–2681.
139. Lawlor DA, Smith GD, Ebrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. *Diabetologia* 2006;**49**:41–48.
140. Wilson PW *et al.* Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;**97**:1837–1847.
141. Knuiman MW, Vu HT. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. *J Epidemiol Community Health* 1997;**51**:515–519.
142. Thomsen TF *et al.* A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. *Int J Epidemiol* 2002;**31**:817–822.
143. Haq IU *et al.* Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. *Heart* 1999;**81**:40–46.
144. D'Agostino RB Sr *et al.* Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA* 2001;**286**:180–187.
145. Game FL, Jones AF. Coronary heart disease risk assessment in diabetes mellitus—a comparison of PROCAM and Framingham risk assessment functions. *Diabet Med* 2001;**18**:355–359.
146. Bastuji-Garin S *et al.* The Framingham prediction rule is not valid in a European population of treated hypertensive patients. *J Hypertens* 2002;**20**:1973–1980.
147. Cappuccio FP *et al.* Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. *BMJ* 2002;**325**:1271.
148. Hense HW *et al.* Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts. *Eur Heart J* 2003;**24**:937–945.
149. Empana JP *et al.* Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. *Eur Heart J* 2003;**24**:1903–1911.
150. Conroy RM *et al.* Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003;**24**:987–1003.
151. EUROASPIRE II Euro Heart Survey Programme. Life style and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. *Eur Heart J* 2001;**22**:554–572.
152. De Bacquer D *et al.* Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. *Eur J Cardiovasc Prev Rehabil* 2003;**10**:289–295.
153. Athyros VG, Papageorgiou AA, Symeonidis AN, Didangelos TP, Pehlivanidis AN, Bouloukos VI, Mikhailidis DP; GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. *Angiology* 2003;**54**:679–690.
154. Arampatzis CA, Goedhart D, Serruys P, Saia F, Lemos P, de Feyter P. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention—A Lescol Intervention Prevention Study (LIPS) substudy. *Am Heart J* 2005;**149**:329–335.
155. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006;**7**:1213–1225.
156. Jeppsson JO, Jerntorp P, Almer LO, Persson R, Ekberg G, Sundkvist G. Capillary blood on filter paper for determination of HbA1c by ion exchange chromatography. *Diabetes Care* 1996;**19**:142–145.
157. The DECODE Study Group. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. *Diabetologia* 2004;**47**:2118–2128.
158. Rose G. Strategy of prevention: lessons from cardiovascular disease. *BMJ (Clin Res Ed)* 1981;**282**:1847–1851.
159. Puska P, Tuomilehto J, Nissinen A, Vartiainen E. The North Karelia Project: 20 year results and experiences. Helsinki: National Public Health Institute; 1995.
160. Yusuf S, Hawken S, Ōunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;**364**:937–952.
161. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB Sr, Wilson PW, Savage PJ. Trends in cardiovascular complications of diabetes. *JAMA* 2004;**292**:2495–2499.
162. Iozzo P, Chareonthaitawee P, Rimoldi O, Betteridge DJ, Camici PG, Ferranini E. Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with type II diabetes. *Diabetologia* 2002;**45**:1404–1409.
163. Silventoinen K *et al.* The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. *Eur J Cardiovasc Prev Rehabil* 2005;**12**:451–458.
164. McNeill AM *et al.* The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. *Diabetes Care* 2005;**28**:385–390.
165. Greenland P *et al.* Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. *JAMA* 2004;**291**:210–215.
166. Braunwald E. Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. *N Engl J Med* 1997;**337**:1360–1369.
167. Akosah KO *et al.* Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? *J Am Coll Cardiol* 2003;**41**:1475–1479.
168. Brindle P *et al.* Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. *BMJ* 2003;**327**:1267.
169. Orford JL *et al.* A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. *Am Heart J* 2002;**144**:95–100.
170. Knowler WC *et al.* Preventing non-insulin-dependent diabetes. *Diabetes* 1995;**44**:483–488.
171. Costacou T, Mayer-Davis EJ. Nutrition and prevention of type 2 diabetes. *Annu Rev Nutr* 2003;**23**:147–170.
172. Hu G *et al.* Occupational, commuting, and leisure-time physical activity in relation to risk for type 2 diabetes in middle-aged Finnish men and women. *Diabetologia* 2003;**46**:322–329.
173. Hu G *et al.* Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. *Arch Intern Med* 2004;**164**:892–896.

174. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. *Diabetologia* 1991;34:891-898.
175. Pan X *et al.* Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* 1997;20:537-544.
176. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferranini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. *Diabetes* 2002;51:3020-3024.
177. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. *Am Heart J* 2006;152:27-38.
178. Chiasson JL *et al.* Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. *Lancet* 2002;359:2072-2077.
179. Lindstrom J *et al.* The Finnish Diabetes Prevention Study (DPS): life style intervention and 3-year results on diet and physical activity. *Diabetes Care* 2003;26:3230-3236.
180. American Diabetes Association. The prevention or delay of type 2 diabetes. *Diabetes Care* 2002;25:742-749.
181. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) Study. *Diabetes Care* 2006;29:1220-1226.
182. Sawicki PT, Kaiser S, Heinemann L, Frenzel H, Berger M. Prevalence of renal artery stenosis in diabetes mellitus—an autopsy study. *J Intern Med* 1991;229:489-492.
183. Wong ND *et al.* Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. *Am J Cardiol* 2003;91:1421-1426.
184. Glumer C *et al.* A Danish diabetes risk score for targeted screening: the Inter99 study. *Diabetes Care* 2004;27:727-733.
185. Spijkerman AM *et al.* The performance of a risk score as a screening test for undiagnosed hyperglycaemia in ethnic minority groups: data from the 1999 health survey for England. *Diabetes Care* 2004;27:116-122.
186. Wei M *et al.* Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. *Ann Intern Med* 2000;132:605-611.
187. Hu FB *et al.* Physical activity and risk for cardiovascular events in diabetic women. *Ann Intern Med* 2001;134:96-105.
188. Batty GD *et al.* Physical activity and cause-specific mortality in men with Type 2 diabetes/impaired glucose tolerance: evidence from the Whitehall study. *Diabet Med* 2002;19:580-588.
189. Gregg EW *et al.* Relationship of walking to mortality among US adults with diabetes. *Arch Intern Med* 2003;163:1440-1447.
190. Tanasescu M *et al.* Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. *Circulation* 2003;107:2435-2439.
191. Hu G *et al.* Occupational, commuting, and leisure-time physical activity in relation to total and cardiovascular mortality among Finnish subjects with type 2 diabetes. *Circulation* 2004;110:666-673.
192. Ong AT, Serruys PW, Mohr FW *et al.* The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. *Am Heart J* 2006;151:1194-1204.
193. American Diabetes Association. Physical activity/exercise and diabetes mellitus. *Diabetes Care* 2003;26(Suppl. 1):S73-S77.
194. Working Party of the international Diabetes Federation (European Region). Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. *Diabet Med* 2003;20:972-987.
195. Luscher TF, Vanhoutte PM. *The Endothelium: Modulator of Cardiovascular Function*. Boca Raton, FL: CRC press; 1991.
196. Luscher TF, Noll G. The endothelium in coronary vascular control. *Heart Dis* 1995;3:1-10.
197. Wever RMF, Luscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. *Circulation* 1998;97:108-112.
198. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. *J Clin Invest* 1991;87:1643-1648.
199. Williams SB, Goldfine AB, Timimi FK *et al.* Acute hyperglycaemia attenuates endothelium-dependent vasodilation in humans in vivo. *Circulation* 1998;97:1695-1701.
200. Nishikawa T, Edelstein D, Du XL *et al.* Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature* 2000;404:787-790.
201. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. *Circulation* 2003;108:1527-1532.
202. Hink U, Li H, Mollnau H *et al.* Mechanisms underlying endothelial dysfunction in diabetes mellitus. *Circ Res* 2001;88:E14-E22.
203. Guzik TJ, Mussa S, Gastaldi D *et al.* Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. *Circulation* 2002;105:1656-1662.
204. Cosentino F, Eto M, De Paolis P *et al.* High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells. *Circulation* 2003;107:1017.
205. Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. *Am J Physiol* 1996;271:C1424-C1437.
206. Van der Lee B, Labugger R, Skepper JN *et al.* Enhanced peroxynitrite formation is associated with vascular aging. *J Exp Med* 2000;192:1731-1744.
207. Turko IT, Murad F. Protein nitration in cardiovascular diseases. *Pharmacol Rev* 2002;54:619-634.
208. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. *Biochem Biophys Res Commun* 1999;263:681-684.
209. Vlassara H, Fuh H, Donnelly T *et al.* Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. *Mol Med* 1995;1:447-456.
210. Tan KC, Chow WS, Ai VH *et al.* Advanced glycation end products and endothelial dysfunction in type 2 diabetes. *Diabetes Care* 2002;25:1055-1059.
211. Park L, Raman KG, Lee KJ *et al.* Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. *Nat Med* 1998;4:1025-1031.
212. Du XL, Edelstein D, Dimmeler S *et al.* Hyperglycaemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. *J Clin Invest* 2001;108:1341-1348.
213. Lin KY, Ito A, Asagami T *et al.* Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. *Circulation* 2002;106:987-992.
214. Williams SB, Cusco JA, Roddy MA *et al.* Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol* 1996;27:567-574.
215. Uzuki LA, Poot M, Gerrity RG *et al.* Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. *Diabetes* 2001;50:851-860.
216. Fukumoto H, Naito Z, Asano G *et al.* Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. *J Atheroscler Thromb* 1998;5:29-35.
217. Bavenholm P, Proudler A, Tornvall P *et al.* Insulin, intact and split proinsulin, and coronary artery disease in young men. *Circulation* 1995;92:1422-1429.
218. Adachi H, Hirai Y, Tsuruta M *et al.* Is insulin resistance or diabetes mellitus associated with stroke? *Diabetes Res Clin Pract* 2001;51:215-223.
219. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. *JAMA* 1995;273:1855-1861.
220. Polonsky KS, Sturis J, Bell GI. Seminars in medicine of the Beth Israel hospital, Boston. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. *N Engl J Med* 1996;21:777-783.
221. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest* 1999;104:787-794.
222. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. *Diabetes Care* 2001;24:89-94.
223. Haffner SM, Miettinen H, Stern MP. Are risk factors for conversion to NIDDM similar in high and low risk populations? *Diabetologia* 1997;40:62-66.
224. Godsland IF, Jeffs JA, Johnston DG. Loss of beta-cell function as fasting glucose increases in the non-diabetic range. *Diabetologia* 2004;47:1157-1166.

225. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. *Diabetologia* 2001;44:929-945.
226. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. *J Clin Endocrinol Metab* 2005;90:493-500.
227. Yeckel CW, Taksali SE, Dziura J, Weiss R, Burgert TS, Sherwin RS, Tamborlane WV, Caprio S. The normal glucose tolerance continuum in obese youth: evidence for impairment in beta-cell function independent of insulin resistance. *J Clin Endocrinol Metab* 2005;90:747-754. Epub November 2, 2004.
228. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. *Diabetes Res Clin Pract* 2004;66(suppl):S37-S43.
229. Yki-Jarvinen H. Glucose toxicity. *Endocr Rev* 1992;13:415-431.
230. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and  $\beta$ -cell dysfunction. *Eur J Clin Invest* 2002;32:14-23.
231. Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, Howard BV. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. *Diabetologia* 1998;41:1127-1132.
232. Wallander M, Bartnik M, Efendic S, Hamsten A, Malmberg K, Öhrvik J, Rydén L, Silveira A, Norhammar A. Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. *Diabetologia* 2005;48:2229-2235.
233. Ting HH, Timimi FK, Boles KS *et al*. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. *J Clin Invest* 1996;97:22-28.
234. Lonn E, Yusuf S, Hoogwerf B *et al*. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. *Diabetes Care* 2002;25:1919-1927.
235. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. *Lancet* 2002;360:7-22.
236. Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. *J Clin Invest* 1994;94:253-259.
237. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. *Ann Intern Med* 2001;135:447-459.
238. Gowri MS, Van der Westhuyzen DR, Bridges SR *et al*. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to abnormal composition of HDL. *Arterioscler Thromb Vasc Biol* 1999;19:2226-2233.
239. Sniderman A, Thomas D, Marpole D *et al*. Low density lipoprotein: a metabolic pathway for return of cholesterol to the splanchnic bed. *J Clin Invest* 1978;61:867-873.
240. Tsai EC, Hirsch IB, Brunzell JD *et al*. Reduced plasma peroxy radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. *Diabetes* 1994;43:1010-1014.
241. Vinik AI, Erbas T, Park TS *et al*. Platelet dysfunction in type 2 diabetes. *Diabetes Care* 2001;24:1476-1485.
242. Assert R, Scherk G, Bumbure A *et al*. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. *Diabetologia* 2001;44:188-195.
243. Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. *Am J Physiol Heart Circ Physiol* 2001;280:H1480-H1489.
244. Hafer-Macko CE, Ivey FM, Gyure KA *et al*. Thrombomodulin deficiency in human diabetic nerve microvasculature. *Diabetes* 2002;51:1957-1963.
245. Ceriello A, Giacomello R, Stel G *et al*. Hyperglycaemia-induced thrombin formation in diabetes: the possible role of oxidative stress. *Diabetes* 1995;44:924-928.
246. Ceriello A, Giugliano D, Quattraro A *et al*. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. *Diabetologia* 1990;33:163-167.
247. Kario K, Matsuo T, Kobayashi H *et al*. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. *Arterioscler Thromb Vasc Biol* 1995;15:1114-1120.
248. Pandolfi A, Cetrullo D, Polishuck R *et al*. Plasminogen activator-inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. *Arterioscler Thromb Vasc Biol* 2001;21:1378-1382.
249. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. *Circulation* 2004;110:894-896.
250. Rodrigues B, Camm MC, McNeill GH. Metabolic disturbances in diabetic cardiomyopathy. *Mol Cell Biochem* 1998;180:53-57.
251. Murray AG, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. *Lancet* 2004;364:1786-1788.
252. Swan GW, Anker SD, Walton C, Godslend EF, Clark AL, Leyva F *et al*. Insulin resistance in chronic failure: relation to severity and etiology of heart failure. *J Am Coll Cardiol* 1997;30:527-532.
253. Pogatsa G. Metabolic energy metabolism in diabetes: therapeutic implications. *Coron Artery Dis* 2001;12(Suppl. 1):S29-S33.
254. Yokoyama I, Monomura S, Ohtake T, Yonekura K, Nishikawa J, Sasaki Y *et al*. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol* 1997;30:1472-1477.
255. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse JS, Thompson MA, Rohrbeck SC *et al*. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. *J Am Coll Cardiol* 1996;28:1661-1669.
256. Ziegler D, Gries FA, Spuler M *et al*. Diabetic cardiovascular autonomic neuropathy multicenter study group: the epidemiology of diabetic neuropathy. *J Diabetes Complications* 1992;6:49-57.
257. O'Brien IA, O'Hara JP, Lewin IG *et al*. The prevalence of autonomic neuropathy in insulin-dependent diabetes: a controlled study based on heart rate variability. *Q J Med* 1986;61:957-967.
258. A desktop to type 2 diabetes mellitus. European Diabetes Policy Group 1999. *Diabetic Med* 1999;16:716-730.
259. Vinik AI, Erbas T. Neuropathy. In Ruderman N, Devlin JT, Schneider SH, Kriska A, eds. *Handbook of Exercise in Diabetes*. Alexandria, VA: American Diabetes Association; 2002. p463-496.
260. Hilsted J, Parving HH, Christensen NJ *et al*. Hemodynamics in diabetic orthostatic hypotension. *J Clin Invest* 1981;68:1427-1434.
261. Burgos LG, Ebert TJ, Assiddao C *et al*. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. *Anesthesiology* 1989;70:591-597.
262. Gerritsen J, Dekker JM, TenVoorde BJ *et al*. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease. The Hoorn Study. *Diabetes Care* 2001;24:1793-1798.
263. Wackers FJT, Joung LH, Inzucchi SE *et al*. Detection of silent myocardial ischaemia in asymptomatic diabetic subjects. The DIAD study. *Diabetes Care* 2004;27:1954-1961.
264. Janand-Delenne B, Savin B, Habib G *et al*. Silent myocardial ischaemia in patients with diabetes. Who to screen. *Diabetes Care* 1999;22:1396-1400.
265. Vinik AL, Erbas T. Recognizing and treating diabetic autonomic neuropathy. *Cleve Clin J Med* 2001;68:928-944.
266. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2005;28:2289-2304.
267. Gale EAM. Editorial: the myth of the metabolic syndrome. *Diabetologia* 2005;10:1873-1875.
268. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. *N Engl J Med* 2005;355:1551-1562.
269. Grundy SM, Brewer HB Jr, Cleeman JI *et al*. Definition of metabolic syndrome report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. *Circulation* 2004;109:433-438.
270. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Arch Intern Med* 2003;163:427-436.
271. Kereciakes DJ, Willerson JT. Metabolic syndrome epidemic. *Circulation* 2003;108:1552.
272. Ferrannini E, Haffner SM, Mitchell BD *et al*. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. *Diabetologia* 1991;34:416-422.
273. Hanley AJ, Williams K, Stern MP *et al*. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. *Diabetes Care* 2002;25:1177-1184.
274. Bogardus C, Lillioja S, Mott DM *et al*. Relationship between degree of obesity and in vivo insulin action in man. *Am J Physiol* 1985;248:e286-e291.

275. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. *J Cardiovasc Risk* 2000; 7:325–331.
276. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. *Diabetes Care* 1999;22(Suppl. 3):C10–C13.
277. Khovidhunkit W, Memon RA, Feingold KR *et al.* Infection and inflammation-induced proatherogenic changes of lipoproteins. *J Infect Dis* 2000;181(Suppl. 3):S462–S472.
278. Jin W, Marchadier D, Rader DJ. Lipases and HDL metabolism. *Trends Endocrinol Metab* 2002;13:174–178.
279. Rocchini AP, Key J, Bondie D *et al.* The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. *N Engl J Med* 1989;321:580–585.
280. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). *J Hypertens* 2001;19:523–528.
281. Festa A, D'Agostino R Jr, Howard G *et al.* Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation* 2000;102:42–47.
282. Schmidt MI, Duncan BB, Sharrett AR *et al.* Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. *Lancet* 1999;353:1649–1652.
283. Pradhan AD, Manson JE, Rifai N *et al.* C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 2001;286:327–334.
284. Ridker PM, Buring JE, Cook NR *et al.* C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. *Circulation* 2003;107:391–397.
285. Festa A, D'Agostino R Jr, Tracy RP *et al.* Elevated levels of acute-phase proteins and plasminogen activator-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. *Diabetes* 2002; 51:1131–1137.
286. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977–986.
287. The Diabetes Control and Complications Trial Research Group. The absence of a glycaemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complication Trial. *Diabetes* 1996;45:1289–1298.
288. Laakso M, Kuusisto J. Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. *Ann Med* 1996;28:415–418.
289. Standl E, Balletshofer B, Dahl B *et al.* Predictors of 10 year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. *Diabetologia* 1996;39:1540–1545.
290. Selvin E, Marinopoulos S, Berkenblit G *et al.* Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med* 2004;141:421–431.
291. UK Prospective Diabetes Study Group (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;352:854–865.
292. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is or is it? *Lancet* 1997;350(Suppl. 1):S1 4–9.
293. Standl E, Schnell O. A new look at the heart in diabetes mellitus: from ailing to failing. *Diabetologia* 2000;43:1455–1469.
294. Haffner SM, Lehto S, Ronnema T *et al.* Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998; 339:229–234.
295. Stratton I, Adler AI, Neil HA *et al.* Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321:405–412.
296. Hu FB, Stamper MJ, Haffner SM *et al.* Elevated risk of cardiovascular disease prior to clinical diagnoses of type 2 diabetes. *Diabetes Care* 2002;25:1129–1134.
297. Khaw KT, Wareham N, Bingham S *et al.* Association of hemoglobin A 1c with cardiovascular disease and mortality in adults: the European prospective investigation into Cancer in Norfolk. *Ann Intern Med* 2004; 141:413–420.
298. Alberti KGMM, Balkau B, Standl E *et al.* Type 2 diabetes and the metabolic syndrome in Europe. *Eur Heart J* 2005;7(Suppl. D):D1–D26.
299. Alberti KGMM. IDF Consensus on the Metabolic Syndrome: Definition and Treatment. 2005 <http://www.idf.org/webcast>.
300. Bonora E, Targher G, Formentini F *et al.* The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona diabetes complications study. *Diabetic Med* 2002;21:52–58.
301. Pastors JG, Warsaw H, Daly H *et al.* The evidence for the effectiveness of medical nutrition therapy in diabetes management. *Diabetes Care* 2002;25: 608–613.
302. Sigal RJ, Kenny GP, Wasserman DH *et al.* Physical activity/exercise and type 2 diabetes. *Diabetes Care* 2004;27: 2518–39.
303. UK Prospective Diabetes Study Group: Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients (UKPDS 7) Metabolism 1990;39: 905–912.
304. NICE. Technology Appraisal 60. Guidance on the use of patient-education models for diabetes. London, National Institute for Clinical Excellence, 2003. [www.nice.org.uk](http://www.nice.org.uk).
305. Gary TL, Genkinger JM, Gualler E *et al.* Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. *The Diabetes Educator* 2003;29:488–501.
306. Laaksonen DE, Lindstrom J, Lakka TA *et al.* Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. *Diabetes* 2005;54:158–165.
307. Diabetes Prevention Research Group. Impact of intensive life style and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Programme. *Diabetes Care* 2005;28:888–894.
308. Franz MJ, Bantle JP, Beebe CA *et al.* Evidence based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care* 2002;25:148–298.
309. Gaede P, Vedel P, Larsen N *et al.* Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003;348:383–393.
310. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. *Can J Diabet* 2003;27(Suppl. 2):1–140. <http://www.diabetes.ca>.
311. Sarol JN, Nicodemus NA, Tan KM *et al.* Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004) *Curr Med Res Opin* 2005;21:173–183.
312. Welschen LMC, Bloemendal E, Nijpels G *et al.* Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. *Diabetes Care* 2005;28:1510–1517.
313. Monnier L, Lapinski H, Colette C Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA<sub>1c</sub>. *Diabetes Care* 2003;26:881–885.
314. Rihl J, Biermann E, Standl E. Insulinresistenz und Typ 2-Diabetes: Die IRIS-Studie. *Diabetes Stoffwechsel* 2002;11:150–158.
315. Okkubo Y, Kishikawa H, Araki E *et al.* Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabet Res Clin Pract* 1995;28:103–117.
316. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005;353:2643–2653.
317. Temelkova-Kurktschiev TS, Koehler C, Henkel E *et al.* Post-challenge plasma glucose and glycaemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA<sub>1c</sub> level. *Diabetes Care* 2000;23:1830–1834.
318. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet* 2006;68: 1096–1105.
319. Reference taken out at proof stage.
320. Dormandy JA, Charbonnel B, Eckland DJ *et al.* Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROActive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005;366:1279–1289.
321. Fava S, Aquilina O, Azzopardi J *et al.* The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. *Diabet Med* 1996;13:80–83.
322. Norhammar AM, Rydén L, Malmberg K. Admission plasma glucose, independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. *Diabetes Care* 1999;22:1827–1831.

323. Malmberg K, Norhammar A, Wedel H *et al.* Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. *Circulation* 1999;**25**: 2626–2632.
324. Otter W, Kleybrink S, Doering W *et al.* Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. *Diabet Med* 2004;**21**:183–187.
325. Malmberg K, Rydén L, Efendic S *et al.* Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI) study: effects on mortality at 1 year. *Am Coll Cardiol* 1995;**26**:57–65.
326. Malmberg, Rydén L, Wedel H *et al.* Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. *Eur Heart J* 2005;**26**:650–661.
327. Schnell O, Doering W, Schäfer O *et al.* Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction. The Munich Registry. *Diabetes Care* 2004;**27**:455–460.
328. American Diabetes Association. Standards of medical care in diabetes. *Diabetes Care* 2005;**28**(Suppl. 1):S4–S36.
329. Häring HU, Joost HG, Laube H *et al.* Antihyperglykämische Therapie des Diabetes mellitus Typ 2. In: Scherbaum WA, Landgraf R, eds. Evidenzbasierte Diabetes-Leitlinie DDG. *Diabetes und Stoffwechsel* 2003;**12**(Suppl. 2). <http://www.deutsche-diabetes-gesellschaft.de> (updated 2004).
330. Turner RC, Cull CA, Frighi V *et al.* UKPDS 49. Glycaemic control with diet, sulphonylurea, metformin and insulin therapy in patients with type 2 diabetes: progressive requirement for multiple therapies. *JAMA* 1999;**281**:2005–2012.
331. Standl E, Fuchtenbusch M. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type 2 diabetes mellitus. *Diabetologia* 2003;**46**(Suppl. 1):M30–M36.
332. Van de Laar FA, Lucassen PL, Akkermans RP *et al.* Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. *Diabetes Care* 2005;**28**:154–163.
333. Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinones and glinides in the treatment of type 2 diabetes mellitus. *Exp Clin Endocr Diab* 2000;**108**:151–163
334. Yki-Järvinen H. Comparison of insulin regimes for patients with type 2 diabetes. *Curr Opin Endocr Diabet* 2000;**7**:175–183.
335. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial. *Diabetes Care* 1993;**16**:434–444.
336. Turner RC, Millns H, Neil HAW *et al.*, for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). *BMJ* 1998;**316**:823–828.
337. Howard BV, Robbins DC, Sievers ML *et al.* LDL cholesterol as a strong risk predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study. *Arterioscler Thromb Vasc Biol* 2000;**20**:830–835.
338. Austin MA, Hokanson JE, Edwards KL. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. *J Cardiovasc Risk* 1996;**3**:213–219.
339. Lehto S, Ronnema T, Haffner SM *et al.* Dyslipidaemia and hypertriglyceridaemia predict coronary heart disease events in middle-aged patients with NIDDM Diabetolo. *Diabetes* 1997;**46**:1354–1359.
340. Lehto S, Ronnema T, Pyorala K *et al.* Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type 2 diabetes. *Diabetologia* 2000;**43**:148–155.
341. Scandinavian Simvastatin Survival Study Group (4S). Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. *Lancet* 1994;**344**:1383–1389.
342. Pyorala K, Pedersen TR, Kjekshus J *et al.* Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). *Diabetes Care* 1997;**20**:614–620.
343. Haffner SM, Alexander CM, Cook TJ *et al.* Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analysis in the Scandinavian Simvastatin Survival Study. *Arch Int Med* 1999;**159**: 2661–2667.
344. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol-lowering in 5963 people with diabetes: a randomized placebo-controlled trial. *Lancet* 2003;**361**:2005–2016.
345. Cannon CP, Braunwald E, McCabe CH *et al.*, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;**350**:1495–1504.
346. LaRosa JC, Grundy SM, Waters DD *et al.*, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005;**352**: 1424–1435.
347. De Backer G, Ambrosioni E, Borch-Johnsen K *et al.* European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on Cardiovascular Disease Prevention in Clinical practice. Executive Summary. *Eur Heart J* 2003;**24**:1601–1610.
348. Grundy SM, Cleeman JI, Merz CNB *et al.*, for the Coordinating Committee of the National Cholesterol Education Programme. Implications of recent clinical trials for the National Cholesterol Education Programme Adult Treatment Panel III Guidelines. *Circulation* 2004;**110**:227–239.
349. Sever PS, Dahlof B, Poulter NR *et al.*, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. *Lancet* 2003;**361**:1149–1158.
350. Colhoun HM, Betteridge DJ, Durrington PN *et al.* Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. *Lancet* 2004;**364**:685–696.
351. Khartlip J, Naglieri R, Mitchell BD, Ryan KA, Donner TW. Screening for silent coronary heart disease in type 2 diabetes: clinical application of American Diabetes Association guidelines. *Diabetes Care* 2006;**29**:692–694.
352. Koskinen P, Mantari M, Manninen V *et al.* Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. *Diabetes Care* 1992;**15**:820–825.
353. Rubins HB, Robins SJ, Collins D *et al.* Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. *N Engl J Med* 1999;**241**:410–418.
354. Rubins HB, Robins SJ, Collins D *et al.* Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High Density Lipoprotein Intervention Trial (VA-HIT). *Arch Intern Med* 2002;**162**:2597–2604.
355. FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. *Lancet* 2005;**366**: 1849–1861.
356. Salomaa VV, Strandberg TE, Vanhanen H, Naukkarinen V, Sarna S, Miettinen TA. Glucose tolerance and blood pressure: long term follow up in middle aged men. *BMJ* 1991;**302**:493–496.
357. Teuscher A, Egger M, Herman JB. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. *Arch Intern Med* 1989;**149**:1942–1945.
358. Baba T, Neugebauer S, Watanabe T. Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention. *Drugs* 1997;**54**:197–234.
359. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993;**16**: 434–444.
360. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT: Multiple Risk Factor Intervention Trial. *JAMA* 1997;**278**:2069–2074.
361. Assman G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. *Circulation* 2002;**105**:310–315.
362. Shehadeh A, Regan TJ. Cardiac consequences of diabetes mellitus. *Clin Cardiol* 1995;**18**:301–305.
363. Leese GP, Vora JP. The management of hypertension in diabetes: with special reference to diabetic kidney disease. *Diabet Med* 1996; **13**:401–410.



364. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998;**317**:703–713.
365. Hansson L, Zanchetti A, Carruthers SG *et al.* Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) trial. *Lancet* 1998;**351**:1755–1762.
366. Nilsson PM, Gudbjörnsdóttir S, Eliasson B, Cederholm J, for the Steering Committee of the National Diabetes Register in Sweden. Hypertension in diabetes: trends in clinical control in repeated national surveys from Sweden 1996–99. *J Hum Hypertens* 2003;**17**:37–44.
367. Anselmino M, Bartnik M, Malmberg K, Rydén L on behalf of the Euro Heart Survey Investigators. Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on diabetes and the heart. *Eur J Cardiovasc Prev Rehab* February 2007, in press. doi 10.1097/01.hjr.0000199496.23838.83.
368. Curb D, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel B, Davis BR, Frost PH, Gonzalez N *et al.* Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. *JAMA* 1996;**276**: 1886–1892.
369. Lieve M, Gueyffier F, Ekblom T *et al.* INDANA Steering Committee. Efficacy of diuretics and -blockers in diabetic hypertensive patients: results from a meta-analysis. *Diabetes Care* 2000;**23**(Suppl. 2):B65–B71.
370. Tuomilehto J, Rastenyte D, Birkenhager WH *et al.* Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. *N Engl J Med* 1999;**340**:677–684.
371. Wang JG, Staessen JA, Gong L, Liu L, Systolic Hypertension in China (Syst-China) Collaborative Group. Chinese trial on isolated systolic hypertension in the elderly. *Arch Intern Med* 2000;**160**:211–220.
372. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 2000;**342**:145–153.
373. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet* 2000;**355**:253–259.
374. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med* 1998;**338**:645–652.
375. Tatti P, Pahor M, Byington RP *et al.* Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998;**21**:597–603.
376. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. *Diabetes Care* 2001;**24**:2091–2096.
377. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. *N Engl J Med* 2004;**351**:1941–1951.
378. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U *et al.* Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet* 2002;**359**:1004–1010.
379. Hansson L, Lindholm LH, Niskanen L *et al.* Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. *Lancet* 1999;**353**:611–616.
380. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;**288**:2981–2997.
381. Whelton PK, Barzilay J, Cushman WC *et al.* Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration and normoglycaemia: Anti-Hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med* 2005;**165**:1401–1409.
382. Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens* 2003;**21**:1011–1053.
383. The Hypertension Detection and Follow-up Programme Cooperative Research Group. Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up programme, stratified by other risk factors. *Prev Med* 1985;**14**:312–335.
384. Lindholm LH, Hansson L, Ekblom T *et al.* Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. *J Hypertens* 2000;**18**:1671–1675.
385. Hansson L, Hedner T, Lund-Johanson P *et al.* Randomized trial of effects of calcium-antagonists compared with diuretics and (blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) Study. *Lancet* 2000;**356**:359–365.
386. Mancia G, Brown M, Castaigne A *et al.* Outcomes with nifedipine GITS or Co-Amizolide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). *Hypertension* 2003;**41**:431–436.
387. Dahlöf B, Sever P, Poulter N *et al.* The enhanced prevention of cardiovascular events with an amlodipine-based regimen compared with an atenolol-based regimen. The Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomized controlled trial. *Lancet* 2005;**366**:895–906.
388. Norhammar A, Malmberg K, Rydén L, Tornvall P, Stenström U, Wallentin L; Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. *Eur Heart J* 2003;**24**:838–844.
389. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Marre M, Steg PG, Gowda N, Gore JM; GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. *Arch Intern Med* 2004;**164**:1457–1463.
390. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, Fioretti PM, Simoons ML, Battler A. A prospective survey on the characteristic, treatments and outcomes of patients with acute coronary syndromes in Europe and Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes. *Eur Heart J* 2002;**23**:1190–1201.
391. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation* 2000;**102**:1014–1019.
392. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. *Lancet* 2002;**359**:2140–2144.
393. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, Tenerz A, Öhrvik J, Rydén L. Abnormal glucose tolerance—a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. *J Intern Med* 2004;**256**:288–297.
394. Pyörälä K, Lehto S, De Bacquer D *et al.* on behalf of the EUROASPIRE I and II Group. Risk factor management in diabetic and non-diabetic coronary heart disease patients. Findings from heart disease patients from EUROASPIRE I and II surveys. *Diabetologia* 2004;**47**:1257–1265.
395. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons ML, Standl E, Soler-Soler J, Öhrvik J, on behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. *Eur Heart J* 2004;**25**: 1880–1890.
396. Bartnik M. Studies on prevalence, recognition and prognostic implications. *Glucose regulation and coronary artery disease*. Karolinska Institutet, Stockholm 2005 (ISBN:91-7140-401-5).
397. Löwel H, Koenig W, Engel S, Hörmann A, Keil U. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. *Diabetologia* 2000;**43**:218–226.
398. van Domburg RT, van Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: good long-term outcome after a complicated early course. *J Am Coll Cardiol* 1998;**31**:1534–1539.
399. Mukamal KJ, Nesto RW, Cohen MC, Nuller JE, Maclure M, Sherwood JB, Mittelman MA. Impact of diabetes on long-term survival after acute myocardial infarction. Comparability of risk with prior myocardial infarction. *Diabetes Care* 2001;**24**:1422–1427.

400. Timmer JR, van der Horst IC, de Luca G, Ottervanger JP, Hoorntje JC, de Boer MJ, Suryapranata H, Dambrink JH, Gosselink M, Zijlstra F, van 't Hof AW; Zwolle Myocardial Infarction Study Group. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. *Am J Cardiol* 2005;**95**:1375–1377.
401. Svensson AM, Abrahamsson P, McGuire DK, Dellborg M. Influence of diabetes on long-term outcome among unselected patients with acute coronary events. *Scand Cardiovasc J* 2004;**38**:229–234.
402. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ, for the GUSTO-I Investigators. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. *J Am Coll Cardiol* 1997;**30**:171–179.
403. McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study. GUSTO IIb Investigators. *Eur Heart J* 2000;**21**:1750–1758.
404. Gitt AK, Schiele R, Wienbergen H, Zeymer U, Schneider S, Gottwik MG, Senges J; MITRA Study. Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study. *Acta Diabetol* 2003;**40**(Suppl. 2):S343–S347.
405. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L, Wallentin L. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. *J Am Coll Cardiol* 2004;**43**:585–591.
406. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALSartan In Acute myocardial infarction (VALIANT) trial. *Circulation* 2004;**21**:1572–1578.
407. Marchioli R, Avanzini F, Barzi F, Chieffo C *et al.* on behalf of GISSI-Prevenzione Investigators. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations. GISSI-Prevenzione mortality chart. *Eur Heart J* 2001;**22**:2085–2103.
408. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. *Arterioscler Thromb Vasc Biol* 2004;**24**:816–823.
409. Malmberg K. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. *BMJ* 1997;**314**:1512–1515.
410. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. *Circulation* 1997;**96**:1152–1156.
411. Diaz R, Paolasso EA, Piegas LS *et al.* on behalf of the ECLA Collaborative Group. Metabolic modulation of acute myocardial infarction. The ECLA Glucose-Insulin-Potassium Pilot Trial. *Circulation* 1998;**98**:2227–2234.
412. Mehta SR, Eikelboom JW, Demers C, Maggioni AP, Commerford PJ, Yusuf S. Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. *Can J Physiol Pharmacol* 2005;**83**:98–103.
413. O'Connor MC, Hathaway WR, Bates ER, Leimberger JD, Sigmon KN, Kereiakes DJ, George BS, Samaha JK, Abbottsmith CW, Candela RJ, Topol EJ, Califf RM. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. *Am Heart J* 1997;**133**:663–673.
414. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW *et al.* Predictors of late development of heart failure in stable survivors of myocardial infarction. The CARE Study. *J Am Coll Cardiol* 2004;**42**:1446–1453.
415. Valeur N, Clemmensen P, Saunamaki K, Grande P, for the DANAMI-2 Investigators. The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study. *Eur Heart J* 2005;**26**:119–127.
416. Campbell RWF, Wallentin L, Verheugt FWA, Turpie AGG, Maseri A, Klein W, Cleland JGF, Bode C, Becker R, Anderson J, Bertrand ME, Conti CR. Management strategies for a better outcome in unstable coronary artery disease. *Clin Cardiol* 1998;**21**:314–322.
417. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FWA, Wijns W; Task Force of the ESC. Acute coronary syndromes acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2003;**24**:28–66.
418. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W; Task Force of the ESC. Acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2002;**23**:1809–1840.
419. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancina G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D *et al*; Third Joint Task Force of the European and other Societies. European Guidelines on Cardiovascular Disease Prevention. *Eur J Cardiovasc Preven Rehab* 2003;**10**(Suppl. 1):S1–S78.
420. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. *Diabet Med* 1999;**16**:716–730. <http://www.staff.ncl.ac.uk/Philip.home/guidelines>.
421. International Diabetes Association 2005—Clinical Guidelines Task Force—Global Guidelines for type 2 Diabetes. <http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf>.
422. Fibrinolytic Therapy Trialists (FFT) Collaborative Group. Indication for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. *Lancet* 1994;**343**:311–322.
423. Mehta SR, Cannon CP, Fox KAA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes. *JAMA* 2005;**293**:2908–2917.
424. Stenestrand U, Wallentin L. Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. *Lancet* 2002;**359**:1805–1811.
425. Lagerqvist B, Kontny F, Näslund U, Ståhle E, Swahn E, Wallentin L and the FRISC-II Investigators. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease. *JACC* 2002;**40**:1902–1914.
426. Freemantle N, Cleland J, Young P *et al.* Beta blockade after myocardial infarction. Systematic review and meta regression analysis. *BMJ* 1999;**318**:1730–1737.
427. Malmberg K, Herlitz J, Hjalmarson Å, Rydén L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large scale studies. *Eur Heart J* 1989;**10**:423–428.
428. Kjekshus J, Gilpin E, Blackey AR, Henning H, Ross J. Diabetic patients and beta-blockers after acute myocardial infarction. *Eur Heart J* 1990;**11**:43–50.
429. Jonas M, Reichel-Reiss H, Boyko V, Shotan A *et al.* for the Bezafibrate Infarction Prevention (BIP) Study Group. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. *Am J Cardiol* 1996;**77**:1273–1277.
430. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. *Cardiovasc Res* 1997;**34**:248–253.
431. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *N Engl J Med* 1998;**339**:489–497.
432. Haas SJ, Vos T, Gilbert RE, Krum H. Are  $\beta$ -blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. *Am Heart J* 2003;**146**:848–853.
433. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C; Task Force on Beta-Blockers of the ESC. Expert consensus document on beta-adrenergic receptor blockers. *Eur Heart J* 2004;**25**:1341–1362.
434. Gheorghiadu M, Goldsten S.  $\beta$ -blockers in the post-myocardial infarction patient. *Circulation* 2002;**106**:394–398.
435. Held PYS, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. *BMJ* 1989;**299**:1187–1192.
436. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. *BMJ* 2002;**324**:71–85.
437. Yusuf S, Zhao F, Mehta SR *et al.* The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. The effects of

- clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494–502.
438. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. *Am J Cardiol* 2002;90:625–628.
  439. Patrono CP, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D *et al.* Expert consensus document on the use of antiplatelet agents. *Eur Heart J* 2004;25:166–181.
  440. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. *Arch Intern Med* 2004;164:2106–2610.
  441. Zuanetti G, Latini R, Maggioni AP *et al.* Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. *Circulation* 1997;96:4239–4245.
  442. Fox KM; EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet* 2003;362:782–788.
  443. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML; EUROPA Investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. *Eur Heart J* 2005;26:1369–1378.
  444. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L; CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. The CREATE-ECLA trial group investigators. *JAMA* 2005;293:437–446.
  445. Van den Berghe G, Wouters PJ, Weekers F *et al.* Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001;345:1359–1367.
  446. Wallner S, Watzinger N, Lindschinger M *et al.* Effects of intensified life style modification on the need for further revascularization after coronary angioplasty. *Eur J Clin Invest* 1999;29:372–379.
  447. Favaloro RG, Effler DB, Groves LK, Sones FM, Fergusson DJ. Myocardial revascularization by internal mammary artery implant procedures. Clinical experience. *J Thorac Cardiovasc Surg* 1967;54:359–370.
  448. Sheldon WC, Favaloro RG, Sones FM, Effler DB. Reconstructive coronary artery surgery. Venous autograft technique. *JAMA* 1970;213:78–82.
  449. Gruentzig A, Hirzel H, Goebel N *et al.* Percutaneous transluminal dilatation of chronic coronary stenoses. First experiences. *Schweiz Med Wochenschr* 1978;108:1721–1723.
  450. Barsness GW, Peterson ED, Ohman EM *et al.* Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. *Circulation* 1997;96:2551–2556.
  451. Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. *J Am Coll Cardiol* 2002;40:418–423.
  452. Thourani VH, Weintraub WS, Stein B *et al.* Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. *Ann Thorac Surg* 1999;67:1045–1052.
  453. Stein B, Weintraub WS, Gebhart SP *et al.* Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. *Circulation* 1995;91:979–989.
  454. Van Belle E, Ketelers R, Bauters C *et al.* Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. *Circulation* 2001;103:1218–1224.
  455. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. *Circulation* 1996;94:1818–1825.
  456. Laskey WK, Selzer F, Vlachos HA *et al.*, for the Dynamic Registry. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). *Am J Cardiol* 2002;90:1062–1067.
  457. Mehran R, Dugas GD, Kobayashi Y *et al.* Short- and long-term results after multivessel stenting in diabetic patients. *J Am Coll Cardiol* 2004;43:1348–1354.
  458. The BARI Investigators. Seven-year outcome in the bypass angioplasty revascularization investigation (BARI) by treatment and diabetic status. *J Am Coll Cardiol* 2000;35:1122–1129.
  459. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation* 1997;96:1761–1769.
  460. Detre KM, Guo P, Holubkov R *et al.* Coronary revascularization in diabetic patients. A comparison of the randomized and observational components of the bypass angioplasty revascularization investigation (BARI). *Circulation* 1999;99:633–640.
  461. Mathew V, Frye RL, Lennon R, Barsness GW, Holmes DR. Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycaemic agents. *Am J Cardiol* 2004;93:399–403.
  462. Ong ATL, Aoki J, van Mieghem CAG *et al.* Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). *Am J Cardiol* 2005;96:358–362.
  463. Kouchoukos NT, Wareing TH, Murphy SF, Pelate C, Marshall WG. Risks of bilateral internal mammary artery bypass grafting. *Ann Thorac Surg* 1990;49:210–217.
  464. Milano CA, Kesler K, Archibald N, Sexton DJ, Jones RH. Mediastinitis after coronary artery bypass graft surgery: risk factors and long-term survival. *Circulation* 1995;92:2245–2251.
  465. Magee MJ, Dewey TM, Acuff T *et al.* Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass. *Ann Thorac Surg* 2001;72:776–781.
  466. Buceri J, Gummert JF, Walther T *et al.* Impact of diabetes mellitus on cardiac surgery outcome. *Thorac Cardiovasc Surg* 2003;51:11–16.
  467. Tang GH, Maganti M, Weisel RD, Borger MA. Prevention and management of deep sternal wound infection. *Semin Thorac Cardiovasc Surg* 2004;16:62–69.
  468. Elezi S, Katrati A, Pache J *et al.* Diabetes and the clinical and angiographic outcome after coronary stent placement. *J Am Coll Cardiol* 1998;32:1866–1873.
  469. Marso SP, Giorgi LV, Johnson WL *et al.* Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. *Am Heart J* 2003;145:270–277.
  470. The Bypass Angioplasty Revascularisation Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. *N Engl J Med* 1996;335:217–225 [Erratum in: *N Engl J Med* 1997;336:147].
  471. Kurbaba AS, Bowker TJ, Ilesley CD, Sigwart U, Rickards AF, the CABRI Investigators. Difference in the mortality of the CABRI diabetic and non-diabetic populations and its relation to coronary artery disease and the revascularization mode. *Am J Cardiol* 2001;87:947–950.
  472. Zhao XQ, Brown BG, Stewart DK *et al.* Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. *Circulation* 1996;93:1954–1962.
  473. Henderson RA, Pocock SJ, Sharp SJ, Nanchahal K, Sculpher MJ, Buxton MJ, Hampton JR. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomized intervention treatment of angina. *Lancet* 1998;352:1419–1425.
  474. Abizaid A, Costa MA, Centemero M *et al.*, the ARTS Investigators. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Insights from the Arterial Revascularization Therapy Study. *Circulation* 2001;104:533–538.
  475. Rodriguez A, Bernardi V, Navia J *et al.*, for the ERACI II Investigators. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. *J Am Coll Cardiol* 2001;37:51–58.
  476. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery Trial): a randomized controlled trial. *Lancet* 2002;360:965–970.
  477. Sedlis SP, Morrison DA, Lorin JD *et al.*, Investigators of the Department of Veterans Affairs Cooperative Study No.385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. *J Am Coll Cardiol* 2002;40:1555–1566.

478. O'Neill WW. Multivessel balloon angioplasty should be abandoned in diabetic patients! *J Am Coll Cardiol* 1998;31:20-22.
479. Niles NW, McGrath PD, Malenka D *et al.*, Northern New England Cardiovascular Disease Study Group. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. *J Am Coll Cardiol* 2001;37:1008-1015.
480. Sabate M, Jimenez-Quevedo P, Angiolillo DJ *et al.*, DIABETES Investigators. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. *Circulation* 2005;112:2175-2183.
481. Finn AV, Palacios IF, Kastrati A, Gold HK. Drug-eluting stents for diabetes mellitus. A rush to judgment? *J Am Coll Cardiol* 2005;45:479-483.
482. Bhatt DL, Marso SP, Lincoff AM, Wolksi KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous intervention. *J Am Coll Cardiol* 2000;35:922-928.
483. Scheen AJ, Warzee F, Legrand VMG. Drug-eluting stents: a meta-analysis in diabetic patients. *Eur Heart J* 2004;25:2167-2168.
484. Eefting F, Nathoe H, van Dijk D *et al.* Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. *Circulation* 2003;108:2870-2876.
485. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. *N Engl J Med* 2005; 352: 2174-2183.
486. Gersh BJ, Frye RL. Methods of coronary revascularization—things may not be as they seem. *N Engl J Med* 2005;352:2235-2237.
487. Marso SP, Ellis SG, Tuzcu EM *et al.* The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. *J Am Coll Cardiol* 1999;33:1269-1277.
488. Schwartz L, Kip KE, Frye RL, Alderman EL, Schaff HV, Detre KM. Coronary bypass graft patency in patients with diabetes in the bypass angioplasty revascularization investigation (BARI). *Circulation* 2002;106:2652-2658.
489. Marso SP. Optimizing the diabetic formulary: beyond aspirin and insulin. *J Am Coll Cardiol* 2002;40:652-661.
490. Breeman A, Hordijk M, Lenzen M *et al.* Treatment decisions in stable coronary artery disease in a broad range of European practices. Insights from the Euro Heart Survey on coronary revascularization. *J Thor Cardiovasc Surg* 2006;132:1001-1009.
491. Gibbons RJ, Abrams J, Chatterjee K *et al.*, American College of Cardiology; American Heart Association task force on practice guidelines. Committee on the management of patients with chronic stable angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). *Circulation* 2003;107:149-158.
492. van Bergen PF, Deckers JW, Jonker JJ, van Domburg RT, Azar AJ, Hofman A. Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. *Br Heart J* 1995;74:117-121.
493. Quinn MJ, Moliterno DJ. Diabetes and percutaneous intervention: the sweet smell of success? *Am Heart J* 2003;145:203-205.
494. Roffi M, Topol EJ. Percutaneous intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. *Eur Heart J* 2004;25:190-198.
495. Angeja BG, de Lemos J, Murphy SA *et al.*, TIMI Study Group. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. *Am Heart J* 2002;144:649-656.
496. O'Neill WW, de Boer MJ, Gibbons RJ *et al.* Lessons from the pooled outcome of the PAMI, Zwolle and Mayo clinic randomized trials of primary angioplasty versus thrombolytic therapy of acute myocardial infarction. *J Invasive Cardiol* 1998;10:4-10.
497. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ, PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. *Am Heart J* 2003;145:47-57.
498. Zijlstra F, Hoorntje JC, de Boer MJ *et al.* Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1999;341:1413-1419.
499. Goraya TY, Leibson CL, Palumbo PJ *et al.* Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. *J Am Coll Cardiol* 2002;40:946-953.
500. Van Belle E, Abolmaali K, Bauters C, McFadden EP, Lablanche J-M, Bertrand ME. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. *J Am Coll Cardiol* 1999;34:476-485.
501. Malmberg K, Rydén L. Myocardial infarction in patients with diabetes mellitus. *Eur Heart J* 1988;9:259-264.
502. Hsu LF, Mak KH, Lau KW *et al.* Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis. *Heart* 2002;88:260-265.
503. Thomas K, Ottervanger JP, de Boer MJ, Suryapranata H, Hoorntje JC, Zijlstra F. Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. *Diabetes Care* 1999; 22:647-649.
504. National Heart, Lung, and Blood Institute (NHLBI). Comparison of two treatments for multivessel coronary artery disease in individuals with diabetes (FREEDOM). <http://www.clinicaltrials.gov/ct/show/NCT00086450>.
505. Kapur A, Malik IS, Bagger JP *et al.* The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. *Am Heart J* 2005;149:13-19.
506. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. *Eur Heart J* 2005;26:1115-1149.
507. von Bibra, Thrainsdottir IS, Hansen A, Dounis V, Malmberg K, Rydén L. Tissue Doppler imaging for the detection and quantification of myocardial dysfunction in patients with type 2 diabetes mellitus. *Diabetes Vasc Dis Res* 2005;2:24-30.
508. Epshteyn V, Morrison K, Krishnaswamy P *et al.* Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. *Diabetes Care* 2003;26:2081-2087.
509. Zannad F, Briancon S, Juilliere Y *et al.*, the EPICAL Investigators. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. *J Am Coll Cardiol* 1999; 33:734-742.
510. Kristiansson K, Sigfusson N, Sigvaldason H, Thorgeirsson G. Glucose tolerance and blood pressure in a population-based cohort study of males and females: the Reykjavik Study. *J Hypertens* 1995;13:581-586.
511. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. *N Engl J Med* 1971;285:1441-1446.
512. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. *Diabetes Care* 2004;27:1879-1884.
513. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women. NHANES I Epidemiologic follow-up study. *Arch Intern Med* 2001;161:996-1002.
514. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men—morbidity, risk factors and prognosis. *J Intern Med* 2001;249:253-261.
515. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A *et al.* Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study. *Eur Heart J* 1999;20:447-455.
516. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K *et al.* The association between glucose abnormalities and heart failure in the population based Reykjavik Study. *Diabetes Care* 2005;28:612-616.
517. Johansson S, Wallander MA, Ruigómez A, Garcia Rodríguez LA. Incidence of newly diagnosed heart failure in UK general practice. *Eur J Heart Fail* 2001;3:225-231.
518. Remes J, Reunanen A, Aromaa A, Pyörala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. *Eur Heart J* 1992;13:588-593.
519. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. *Am J Cardiol* 1974;34:29-34.
520. Amato L, Paolisso G, Cacciatore F *et al.* on behalf of the Osservatorio Geriatrico Regione Campania Group. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. *Diabetes Med* 1997;23:213-218.
521. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A *et al.* The prognosis of heart failure in the general population. The Rotterdam Study. *Eur Heart J* 2001;22:1318-1327.

522. De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E *et al.* Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. *Eur Heart J* 2004;25:656–662.
523. Thrainsdottir IS, Aspelund T, Hardarson T, Malmberg K, Sigurdsson G, Thorgeirsson G, Gudnason V, Rydén L. Glucose abnormalities and heart failure predict poor prognosis in the population based Reykjavik Study. *Eur J Cardiovasc Prev Rehabil* 2005;12:465–471.
524. Solang L, Malmberg K, Rydén L. Diabetes mellitus and congestive heart failure. *Eur Heart J* 1999;20:789–795.
525. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet* 1993;342:821–828.
526. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D *et al.* Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. *Circulation* 1992;86:431–438.
527. Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S *et al.* Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. *Am Heart J* 2000;139:1081–1087.
528. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. *N Engl J Med* 1987;316:1429–1435.
529. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ *et al.* on behalf of the ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE-II. *Lancet* 2000;355:1582–1587.
530. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. *N Engl J Med* 1991;325:293–302.
531. Rydén L, Armstrong PW, Cleland JG *et al.* Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. *Eur Heart J* 2000;21:1967–1978.
532. Pfeffer M, Braunwald E, Moyé *et al.* on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 1992;327:669–677.
533. Moyé LA, Pfeffer MA, Wun CC *et al.* Uniformity of captopril benefit in the SAVE study: subgroup analysis. Survival and ventricular enlargement study. *Eur Heart J* 1994;15(Suppl. B):2–8.
534. Herings RMC, deBoer A, Stricker BHC, Leufkens HGM, Porsius A. Hypoglycaemia associated with the use of inhibitors of angiotensin-converting enzyme. *Lancet* 1996;345:1195–1198.
535. Morris AD, Boyle DIR, McMahon AD *et al.* ACE inhibitor use is associated with hospitalization for severe hypoglycaemia in patients with diabetes. *Diabetes Care* 1997;20:1363–1379.
536. Dickstein K, Kjekshus J; the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. *Lancet* 2002;360:752–760.
537. Pfeffer MA, McMurray JJ, Velazques EJ *et al.* for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;349:1893–1906.
538. Granger CB, McMurray JJV, Yusuf S *et al.* for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative Trial. *Lancet* 2003;362:772–776.
539. Opie LH, Thomas M. Propranolol and experimental myocardial infarction: substrate effects. *Postgrad Med J* 1976;52(Suppl. 4):124–133.
540. Dávila-Román VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP *et al.* Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. *J Am Coll Cardiol* 2002;40:271–277.
541. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. *Lancet* 1999;353:9–13.
542. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J *et al.* for the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). *JAMA* 2000;283:1295–1302.
543. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J; MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. *Am Heart J* 2005;149:159–167.
544. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacci P *et al.* for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001;344:1651–1658.
545. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M *et al.* for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. *Lancet* 2003;362:7–13.
546. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. *Clin Pharmacol Ther* 1995;57:601–609.
547. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999;341:709–717.
548. Parsonage WA, Hetmanski D, Cowley AJ. Beneficial haemodynamic effects of insulin in chronic heart failure. *Heart* 2001;85:508–513.
549. McNulty PH, Pfau S, Deckelbaum LI. Effect of plasma insulin level on myocardial blood flow and its mechanism of action. *Am J Cardiol* 2000;85:161–165.
550. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. *Am Heart J* 2005;149:168–174.
551. Khoury VK, Haluska B, Prins J, Marwick TH. Effects of glucose–insulin–potassium infusion on chronic ischaemic left ventricular dysfunction. *Heart* 2003;89:61–65.
552. American Diabetes Association: Clinical Practice Recommendations 2004. *Diabetes Care* 2004;27(Suppl. 1):S5–S19.
553. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. *Clin Sci* 2000;99:27–35.
554. Fragasso G, Piatti PM, Monti L, Pallosi A, Setola E, Puccetti P *et al.* Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. *Am Heart J* 2003;146:E18.
555. Thrainsdottir IS, von Bibra H, Malmberg K, Rydén L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. *J Cardiovasc Pharmacol* 2004;44:101–108.
556. Lewis JF, DaCosta M, Wargowich T, Stacpoole P. Effects of dichloroacetate in patients with congestive heart failure. *Clin Cardiol* 1998;21:888–889.
557. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991;22:983–988.
558. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the ATRIA Study. *JAMA* 2001;285:2370–2375.
559. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Silent myocardial ischemia Silent myocardial ischaemia VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). *Am J Cardiol* 1994;74:236–241.
560. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. *Circulation* 1997;96:2455–2461.
561. Levy S, Maarek M, Coumel P *et al.* Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. *Circulation* 1999;99:3028–3035.
562. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med* 1995;98:476–484.
563. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *JAMA* 1994;271:840–844.
564. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. *Lancet* 1987;1:526–529.
565. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. *Arch Intern Med* 1994;154:1449–1457.

566. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. *Arch Intern Med* 1987;147:1561-1564.
567. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. *Stroke* 1994;25:1157-1164.
568. Davis TME, Millns H, Stratton IM, Holman RR, Turner RC, for the UK Prospective Diabetes Study Group. Risk factors for stroke in type 2 diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS). *Arch Intern Med* 1999;159:1097-1103.
569. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen ATRIAL FIBRILLATION/ASAK Study. *Lancet* 1989; 1:175-179.
570. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, for the CATRIAL FIBRILLATION Study Coinvestigators. Canadian Atrial fibrillation Anticoagulation (CATRIAL FIBRILLATION) Study. *J Am Coll Cardiol* 1991;18:349-355.
571. The Boston Area Anticoagulation Trial for Atrial fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med* 1990;323:1505-1511.
572. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. *Stroke* 1999; 30:1223-1229.
573. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. *N Engl J Med* 1992;327:1406-1412.
574. The Stroke Prevention in Atrial fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. 1. Clinical features of patients at risk. *Ann Intern Med* 1992;116:1-5.
575. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, Halperin JL, for the Stroke prevention in atrial fibrillation investigators. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (the Stroke Prevention in Atrial fibrillation [SPAF] FIBRILLATION-III Study). *J Am Soc Echocardiogr* 1999;12:1080-1087.
576. Illien S, Maroto-Jarvinen S, von der Recke G, Hammerstingl C, Schmidt H, Kuntz-Hehner S, Luderitz B, Omran H. Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism. *Heart* 2003;89:165-168.
577. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med* 1999;131:492-501.
578. Albers GW, Dalen JE, Laupacis A *et al.* Antithrombotic therapy in atrial fibrillation. *Chest* 2001;119:194S-206S.
579. SPATRIAL FIBRILLATION Investigators. The Stroke Prevention in Atrial fibrillation III Study: rationale, design and patient features. *J Stroke Cerebrovasc Dis* 1997;5:341-353.
580. Gage BF, Waterman AD, Shannon W *et al.* Validation of clinical classification schemes for predicting stroke: results from the National Registry of atrial fibrillation. *JAMA* 2001;285:2864-2870.
581. Wang TJ, Massaro JM, Levy D *et al.* A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. *JAMA* 2003;290:1049-1056.
582. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, Petersen P. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. *Circulation* 2004;110:2287-2292.
583. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. *Eur Heart J* 2006;27:1979-2030.
584. Singer DE, Albers GW, Dalen JA, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:429-456.
585. Priori SG, Altiot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Cappato R, Cobbe SM, Di Mario C, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz PJ, Trusz-Gluzka M, Vardas P, Wellens HJ, Zipes DP. Task Force on Sudden Cardiac Death of the European Society of Cardiology. *Eur Heart J* 2001;22:1374-1450.
586. Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. *Am Heart J* 1998;136:205-212.
587. Albert CM, Chae CU, Grodstein F, Rose LM, Rexrode KM, Ruskin JN, Stampfer MJ, Manson JE. Prospective study of sudden cardiac death among women in the United States. *Circulation* 2003;107:2096-2101.
588. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K. Related articles. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. *Circulation* 1995;91:2591-2595.
589. Balkau B, Jouven X, Ducimetiere P, Eschwege E. Diabetes as a risk factor for sudden death. *Lancet* 1999;354:1968-1969.
590. Jouven X, Lemaître RN, Rea TD, Sotoodehnia N, Empana JP, Siscovick DS. Diabetes, glucose level, and risk of sudden cardiac death. *Eur Heart J* 2005;26:2142-2147.
591. Cosentino F, Egidy Assenza G. Diabetes and inflammation. *Herz* 2004; 29:749-759.
592. O'Brien IA, Mc Fadden JP, Corral RJM. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. *Q J Med* 1991;79: 495-502.
593. Forsen A, Kangro M, Sterner G, Norrgren K, Thorsson O, Wollmer P, Sundkvist G. A 14-year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy. *Diabet Med* 2004;21:852-858.
594. Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. *J Endocrinol Invest* 2004; 27:175-181.
595. Rozanski GJ, Xu Z. A metabolic mechanism for cardiac K<sup>+</sup> channel remodeling. *Clin Exp Pharmacol Physiol* 2002;29:132-137.
596. Ewing DJ, Compbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. *Q J Med* 1980;49:95-108.
597. Gerritsen J, Dekker JM, TenVoorde BJ, Bertelsmann FW, Kostense PJ, Stehouwer CD, Heine RJ, Nijpels G, Heethaar RM, Bouter LM. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. *Diabetologia* 2000;43:561-570.
598. Ewing DJ, Boland O, Neilson JM *et al.* Autonomic neuropathy, QT interval lengthening and unexpected deaths in male diabetic patients. *Diabetologia* 1991;34:182-185.
599. Navarro X, Kennedy WR, Lowenson RB *et al.* Influence of pancreas transplantation on cardiorepiratory reflexes, nerve conduction and mortality in diabetes mellitus. *Diabetes* 1990;39:802-806.
600. Singh JP, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, Levy D. Association of hyperglycaemia with reduced heart rate variability (The Framingham Heart Study). *Am J Cardiol* 2000;86:309-312.
601. Schroeder EB, Chambless LE, Liao D, Prineas RJ, Evans GW, Rosamond WD, Heiss G; Atherosclerosis Risk in Communities (ARIC) Study. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) Study. *Diabetes Care* 2005;28:668-674.
602. Suarez GA, Clark VM, Norell JE, Kottke TE, Callahan MJ, O'Brien PC, Low PA, Dyck PJ. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. *J Neurol Neurosurg Psychiatry* 2005;76:240-245.
603. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA* 2002;287: 2570-2581.
604. Meijer WT, Hoes AW, Rutgers D *et al.* Peripheral arterial disease in the elderly: the Rotterdam Study. *Arterioscler Thromb Vasc Biol* 1998;18: 185-192.
605. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. *Circulation* 1995;91:1472-1479.
606. Jude EB, Oyibo SO, Chalmers N *et al.* Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. *Diabetes Care* 2001;24:1433-1437.
607. Mozes G, Keresztury G, Kadar A, Magyar J, Sipos B, Dzinich S, Glociczki P. Atherosclerosis in amputated legs of patients with and without diabetes mellitus. *Int Angiol* 1998;17:282-286.
608. Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH: Medial arterial calcification and its association with mortality and complications of diabetes. *Diabetologia* 1988;31:16-23.
609. Dormandy JA, Rutherford RB; TASC Working Group. TransAtlantic Inter-Society Consensus (TASC), Management of peripheral arterial disease (PAD). *J Vasc Surg* 2000;31:51-5296.
610. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. *Lancet* 2005;366:1725-1735.
611. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. *N Engl J Med* 2001;344:1608-1621.

612. Hess H, Mietaschik A, Deichsel G. Drug induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double blind arteriographic controlled trial. *Lancet* 1985;1:416-419.
613. Caprie Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). *Lancet* 1996;348:1329-1339.
614. Kalani M, Apelqvist J, Blomback M *et al.* Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. *Diabetes Care* 2003;26:2575-2580.
615. Loosemore T, Chalmers T, Dormandy J. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. *Int Angiol* 1994;13:133-142.
616. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. *Diabetologia* 1995;38:1061-1068.
617. Mankovsky BN, Ziegler D. Stroke in patients with diabetes mellitus. *Diabetes Metab Res Rev* 2004;20:268-287.
618. Folsom AR, Rasmussen ML, Chambless ME *et al.* Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. *Diabetes Care* 1999;22:1077-1083.
619. Miettinen H, Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M, Roehmboldt ME, Palumbo PJ, Whisnant JP, Elveback LP. Proteinuria predicts stroke and other atherosclerotic vascular disease events in non-diabetic and non-insulin-dependent diabetic subjects. *Stroke* 1996;27:2033-2039.
620. Toyry JP, Niskanen LK, Lansimies EA, Partanen KP, Uusitupa MI. Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. *Stroke* 1996;27:1316-1318.
621. Transient ischemic attack and stroke in a community-based diabetic cohort. *Mayo Clin Proc* 1983;58:56-58.
622. Laing SP, Swerdlow AJ, Carpenter LM, Slater SD, Burden AC, Botha JL, Morris AD, Waugh NR, Gatling W, Gale EA, Patterson CC, Qiao, Z, Keen, H. Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. *Stroke* 2003;34:418-421.
623. Johnston CS, Sidney S, Bernstein AL, Gress DR. A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA. *Neurology* 2003;28:280-285.
624. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001;358:1033-1041.
625. Colwell JA. Aspirin therapy in diabetes (Technical review). *Diabetes Care* 1997;20:1767-1771.
626. Sivenius J, Laakso M, Piekkinen Sr, Smets P, Lowenthal A. European stroke prevention study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke. *Stroke* 1992;23:851-854.
627. Diener F, Coccheri S, Libretti A *et al.* European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci* 1996;143:1-13.
628. Diener F, Bogousslavsky J, Brass LM *et al.* Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. *Lancet* 2004;364:331-337.
629. Bhatt DL, Fox KA, Hacke W *et al.* for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med* 2006;354:1706-1717.
630. Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. *J Am Coll Cardiol* 2004;43:929-935.
631. Imray CH, Tiivas CA. Are some strokes preventable? The potential role of transcranial doppler in transient ischaemic attacks of carotid origin. *Lancet Neurol* 2005;4:580-586.
632. Goldstein LB, Adams R, Becker K *et al.* Primary prevention of ischemic stroke. A statement for health care professionals from the stroke council of the American Heart Association. *Stroke* 2001;32:280-293.
633. Tu JV, Wang H, Bowyer B, Green L, Fang J, Kucey D. Risk factors for death or stroke after carotid endarterectomy. Observations from the Ontario Carotid Endarterectomy Registry. *Stroke* 2003;34:2568-2573.
634. Goodney PP, Schermehorn ML, Powell RJ. Current status of carotid artery stenting. *J Vasc Surg* 2006;43:406-411.
635. Wardlaw JM, delZoppo GJ, Yamaguchi T. Thrombolysis in acute ischemic stroke (Cochrane review). In: *The Cochrane Library*, Issue 2. Oxford Update Software 2002.
636. Sulter G, Elting JW, Langedijk M *et al.* Admitting acute ischemic stroke patients to a stroke care monitoring unit versus a conventional stroke unit: a randomized pilot study. *Stroke* 2003;34:101-104.
637. European Stroke Initiative Executive and Writing Committee. The European stroke initiative recommendations for stroke management: update 2003. *Cerebrovasc Dis* 2003;314:1303-1306.
638. Thorell A, Nygren J, Ljungqvist O. Insulin resistance: a marker of surgical stress. *Curr Opin Clin Nutr Metab Care* 1999;21:69-78.
639. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycaemia. *Crit Care Clin* 2001;17:107-124.
640. Hill M, McCallum R. Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. *J Clin Invest* 1991;88:811-816.
641. Khani S, Tayek JA. Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. *Clin Sci (Lond.)* 2001;101:739-747.
642. Watt MJ, Howlett KF, Febbraio MA *et al.* Adrenalin increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans. *J Physiol* 2001;534:269-278.
643. Flores EA, Istfan N, Pomposelli JJ *et al.* Effect of interleukin-1 and tumor necrosis factor/cachectin on glucose turnover in the rat. *Metabolism* 1990;39:738-743.
644. Sakurai Y, Zhang XJ, Wolfe RR. TNF directly stimulates glucose uptake and leucine oxidation and inhibits FFA flux in conscious dogs. *Am J Physiol* 1996;270:E864-E872.
645. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. *Endocrinology* 1992;130:43-52.
646. Capes SE, Hunt D, Malmberg K *et al.* Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet* 2000;355:773-778.
647. Muhlestein JB, Anderson JL, Horne BD *et al.* Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. *Am Heart J* 2003;146:351-358.
648. Suematsu Y, Sato H, Ohtsuka T *et al.* Predictive risk factors for delayed extubation in patients undergoing coronary artery bypass grafting. *Heart Vessels* 2000;15:214-220.
649. Krinsley JS. Association between hyperglycaemia and increased hospital mortality in a heterogeneous population of critically ill patients. *Mayo Clin Proc* 2003;78:1471-1478.
650. Faustino EV, Apkon M. Persistent hyperglycaemia in critically ill children. *J Pediatr* 2005;146:30-34.
651. Capes SE, Hunt D, Malmberg K *et al.* Stress hyperglycaemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. *Stroke* 2001;32:2426-2432.
652. Rovlias A, Kotsou S. The influence of hyperglycaemia on neurological outcome in patients with severe head injury. *Neurosurgery* 2000;46:335-342.
653. Jeremitsky E, Omert LA, Dunham M *et al.* The impact of hyperglycaemia on patients with severe brain injury. *J Trauma* 2005;58:47-50.
654. Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyperglycaemia as a prognostic indicator in trauma. *J Trauma* 2003;55:33-38.
655. Laird AM, Miller PR, Kilgo PD *et al.* Relationship of early hyperglycaemia to mortality in trauma patients. *J Trauma* 2004;56:1058-1062.
656. Gore DC, Chinkes D, Heggors J *et al.* Association of hyperglycaemia with increased mortality after severe burn injury. *J Trauma* 2001;51:540-544.
657. Ingels C, Debaveye Y, Milants I, Buelens E, Peeraer A, Devriendt Y, Vanhoutte T, Van Damme A, Schetz M, Wouters PJ, Van den Berghe G. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. *Eur Heart J* 2006;27:2716-2724.
658. Van den Berghe G, Schoonheydt K, Bex P *et al.* Insulin therapy protects the central and peripheral nervous system of intensive care patients. *Neurology* 2005;64:1348-1353.
659. Van den Berghe G, Wilmer A, Hermans G *et al.* Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006;354:449-461.
660. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. *Mayo Clin Proc* 2004;79:992-1000.
661. Grey NJ, Perdrizet GA. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycaemic control. *Endocr Pract* 2004;10(Suppl. 2):46-52.

662. Furnary AP, Wu Y, Bookin SO. Effect of hyperglycaemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. *Endocr Pract* 2004;**10** (Suppl. 2):21–33.
663. Chaney MA, Nikolov MP, Blakeman BP, Bakhos M. Attempting to maintain normoglycaemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycaemia. *Anesth Analg* 1999;**89**: 1091–1095.
664. Carvalho G, Moore A, Qizilbash B *et al.* Maintenance of normoglycaemia during cardiac surgery. *Anesth Analg* 2004;**99**:319–324.
665. Van den Berghe G, Wouters PJ, Bouillon R *et al.* Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycaemic control. *Crit Care Med* 2003;**31**:359–366.
666. Finney SJ, Zekveld C, Elia A *et al.* Glucose control and mortality in critically ill patients. *JAMA* 2003;**290**:2041–2047.
667. Klip A, Tsakiridis T, Marette A, Ortiz PA. Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures. *FASEB J* 1994;**8**:43–53.
668. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? *J Clin Invest* 2004;**114**:1187–1195.
669. Vanhorebeek I, De Vos R, Mesotten D *et al.* Strict blood glucose control with insulin in critically ill patients protects hepatocytic mitochondrial ultrastructure and function. *Lancet* 2005;**365**:53–59.
670. Langouche L, Vanhorebeek I, Vlasselaers D *et al.* Intensive insulin therapy protects the endothelium of critically ill patients. *J Clin Invest* 2005;**115**:2277–2286.
671. Weekers F, Giuletti A-P, Michalaki M *et al.* Endocrine and immune effects of stress hyperglycaemia in a rabbit model of prolonged critical illness. *Endocrinology* 2003;**144**:5329–5338.
672. Mesotten D, Swinnen JV, Vanderhoydonc F *et al.* Contribution of circulating lipids to the improved outcome of critical illness by glycaemic control with intensive insulin therapy. *J Clin Endocrinol Metab* 2004;**89**:219–226.
673. Hansen TK, Thiel S, Wouters PJ *et al.* Intensive insulin therapy exerts anti-inflammatory effects in critically ill patients, as indicated by circulating mannose-binding lectin and C-reactive protein levels. *J Clin Endocrinol Metab* 2003;**88**:1082–1088.
674. Das UN. Insulin: an endogenous cardioprotector. *Curr Opin Crit Care* 2003;**9**:375–383.
675. Jonassen A, Aasum E, Riemersma R *et al.* Glucose-insulin-potassium reduces infarct size when administered during reperfusion. *Cardiovasc Drugs Ther* 2000;**14**:615–623.
676. Gao F, Gao E, Yue T *et al.* Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischaemia-reperfusion: the role of PI3-kinase, Akt and eNOS phosphorylation. *Circulation* 2002;**105**:1497–1502.
677. Jonassen A, Sack M, Mjos O, Yellon D. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70S6 kinase cell-survival signalling. *Circ Res* 2001;**89**:1191–1198.
678. Bothe W, Olschewski M, Beyersdorf F, Doenst T. Glucose-insulin-potassium in cardiac surgery: a meta-analysis. *Ann Thorac Surg* 2004;**78**:1650–1657.
679. Pagano E, Brunetti M, Tediosi F *et al.* Costs of diabetes. A methodological analysis of the literature. *Pharmacoeconomics* 1999;**15**:583–595.
680. Songer TJ. The economic costs of NIDDM. *Diabetes Metab Rev* 1992;**8**: 389–404.
681. American Diabetes Association. *Direct and indirect costs of diabetes in the United States in 1987*. Alexandria, VA: ADA; 1987.
682. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. American Diabetes Association. *Diabetes Care* 1994;**17**:616–623.
683. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. *Diabetes Care* 1998;**21**:296–309.
684. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. *Diabetes Care* 2003;**26**:917–932.
685. Huse DM, Oster G, Killen AR *et al.* The economic costs of non-insulin-dependent diabetes mellitus. *JAMA* 1989;**262**:2708–2713.
686. Kegler MC, Lengerich EJ, Norman M *et al.* The burden of diabetes in North Carolina. *N C Med J* 1995;**56**:141–144.
687. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. *J Clin Endocrinol Metab* 1994;**78**:809A–809F.
688. Warner DC, McCandless RR, De Nino LA *et al.* Costs of diabetes in Texas, 1992. *Diabetes Care* 1996;**19**:1416–1419.
689. Barcelo A, Aedo C, Rajpathak S *et al.* The cost of diabetes in Latin America and the Caribbean. *Bull World Health Organ* 2003;**81**:19–27.
690. Chale SS, Swai AB, Mujinja PG *et al.* Must diabetes be a fatal disease in Africa? Study of costs of treatment. *BMJ* 1992;**304**:1215–1218.
691. Dawson KG, Gomes D, Gerstein H *et al.* The economic cost of diabetes in Canada, 1998. *Diabetes Care* 2002;**25**:1303–1307.
692. Lin T, Chou P, Lai MS *et al.* Direct costs-of-illness of patients with diabetes mellitus in Taiwan. *Diabetes Res Clin Pract* 2001;**54**(Suppl. 1):S43–S46.
693. McKendry JB. Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. *Can J Public Health* 1989;**80**:124–128.
694. Phillips M, Salmeron J. Diabetes in Mexico—a serious and growing problem. *World Health Stat Q* 1992;**45**:338–346.
695. Gerard K, Donaldson C, Maynard AK. The cost of diabetes. *Diabet Med* 1989;**6**:164–170.
696. Gray A, Fenn P, McGuire A. The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. *Diabet Med* 1995;**12**:1068–1076.
697. Henriksson F, Jonsson B. Diabetes: the cost of illness in Sweden. *J Intern Med* 1998;**244**:461–468.
698. Henriksson F, Agardh CD, Berne C *et al.* Direct medical costs for patients with type 2 diabetes in Sweden. *J Intern Med* 2000;**248**:387–396.
699. Jonsson B. Diabetes—the cost of illness and the cost of control. An estimate for Sweden 1978. *Acta Med Scand Suppl* 1983;**671**:19–27.
700. Kangas T, Aro S, Koivisto VA *et al.* Structure and costs of health care of diabetic patients in Finland. *Diabetes Care* 1996;**19**:494–497.
701. Lucioni C, Garancini MP, Massi-Benedetti M *et al.* The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. *Treat Endocrinol* 2003;**2**:121–133.
702. Oliva J, Lobo F, Molina B *et al.* Direct health care costs of diabetic patients in Spain. *Diabetes Care* 2004;**27**:2616–2621.
703. Spri, Diabetesvården i vågskålen. Yngre och medelålders diabetiker rapporterar om vårdutnyttjande, ekonomi och kvalitet. Spri rapport 451. ISSN 0586–1691. 1997, Spri: Stockholm.
704. Triomphe A, Flori YA, Costagliola D *et al.* The cost of diabetes in France. *Health Policy* 1988;**9**:39–48.
705. Jonsson B. Health economic aspects of diabetes. *Endocrinol Metab* 1997;**4**(Suppl. B):135–137.
706. Jonsson B. Revealing the cost of Type II diabetes in Europe. *Diabetologia* 2002;**45**:S5–S12.
707. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. *Diabetologia* 2002;**45**:S13–S17.
708. Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. *Diabetologia* 1999;**42**:1293–1301.
709. Mihaylova B, Briggs A, Armitage J *et al.* Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomized trial in 20,536 individuals. *Lancet* 2005;**365**:1779–1785.
710. Clarke PM, Gray AM, Briggs A *et al.* Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). *Diabetologia* 2005;**48**:868–877.
711. Casciano J, Doyle J, Casciano R *et al.* The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. *Int J Clin Pract* 2001;**55**:84–92.